Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN

NCT07363460 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Lupus Nephritis (LN)

Interventions

DRUG: HSK39297 200mgQD
DRUG: HSK39297 300mgQD
DRUG: Placebo

Sponsor

Haisco Pharmaceutical Group Co., Ltd.